Pune-based Serum of Institute of India (SII) is likelty to start clinical trials of the Novavax's Covid-19 vaccine candidate on children from next month, reports Indian Express.
SII has partnered with the United States based Novavax to manufacture its recombinant nanoparticle protein-based vaccine - NVX-CoV2373 in India. The Novavax vaccine has been branded as Covovax in India.
The Covovax is alsoo in advanced stages of Phase 2 and 3 bridging trials with the Serum Institute enrolling 1,600 participants over 18 years across 15 sites.
The Pune-based vaccine maker expects to launch the Covovax in India in September.
If and when SII is allowed by the Indian drug regulator to conduct the clinical trials of Covovax on children, the vaccine would become the third jab to be tested on paediatric population in India. Bharat Biotech's Covaxin and Zydus Cadila's ZyCoV-D are the two other vaccines currently being tested on children in the country.
Novavax had earlier this week announced that its Covid-19 vaccine has shown over 90 per cent efficacy in the late stage, large clinical trials of the jab in United States and Mexico.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.